Phase I/II Trial of Durvalumab and Tremelimumab with Continuous or Intermittent MEK Inhibitor Selumetinib in Advanced NSCLC

被引：0
|
作者：
Gaudreau, P. [1 ]
Heymach, J. [2 ]
Gibbons, D. [2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
MEK inhibitor; advanced NSCLC; Immune checkpoint blockade;
D O I：
10.1016/j.jtho.2019.08.1542
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.04-37
引用
收藏
页码：S722 / S723
页数：2
相关论文
共 50 条
  • [1] Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report
    Gaudreau, Pierre-Olivier
    Lee, J. Jack
    Heymach, John, V
    Gibbons, Don L.
    CLINICAL LUNG CANCER, 2020, 21 (04) : 384 - 388
  • [2] Phase I trial evaluating MEK inhibitor selumetinib with concomitant thoracic radiotherapy in NSCLC
    Haslett, K.
    Blackhall, F.
    Koh, P.
    Ashcroft, L.
    Asselin, M.
    Harris, C.
    Jackson, A.
    Manoharan, P.
    Mullan, D.
    Ryder, W.
    Taylor, B.
    Faivre-Finn, C.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S387 - S387
  • [3] Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
    Jain, Nitin
    Curran, Emily
    Iyengar, Neil M.
    Diaz-Flores, Ernesto
    Kunnavakkam, Rangesh
    Popplewell, Leslie
    Kirschbaum, Mark H.
    Karrison, Theodore
    Erba, Harry P.
    Green, Margaret
    Poire, Xavier
    Koval, Greg
    Shannon, Kevin
    Reddy, Poluru L.
    Joseph, Loren
    Atallah, Ehab L.
    Dy, Philip
    Thomas, Sachdev P.
    Smith, Scott E.
    Doyle, L. Austin
    Stadler, Walter M.
    Larson, Richard A.
    Stock, Wendy
    Odenike, Olatoyosi
    CLINICAL CANCER RESEARCH, 2014, 20 (02) : 490 - 498
  • [4] A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
    Chenard-Poirier, Maxime
    Hansen, Aaron R.
    Gutierrez, Martin E.
    Rasco, Drew
    Xing, Yan
    Chen, Lin-Chi
    Zhou, Heng
    Webber, Andrea L.
    Freshwater, Tomoko
    Sharma, Manish R.
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (03) : 241 - 251
  • [5] Tremelimumab plus Durvalumab Prior to Chemoradiotherapy in Unresectable Locally Advanced NSCLC, the Induction Trial
    Smeenk, M. M.
    van Diessen, J. N. A.
    Boellaard, T. N.
    Hartemink, K. J.
    de Vries, J. F.
    Badrising, S. K.
    Wondergem, M.
    Wittenberg, R.
    Monkhorst, K.
    van den Heuvel, M. M.
    Theelen, W. S. M. E.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S157 - S157
  • [6] Multi-center phase Ib study of intermittent dosing of the MEK inhibitor, selumetinib, in patients with advanced uveal melanoma not previously treated with a MEK inhibitor.
    Komatsubara, Kimberly Mayumi
    Shoushtari, Alexander Noor
    Patel, Sapna Pradyuman
    Momtaz, Parisa
    Singh-Kandah, Shahnaz
    Carter, Amanda
    Cain, Suzanne
    Taiclet, Lauren
    DeNoble, Sarah
    Negri, Tiffany
    Lacey, Danielle
    Ambrosini, Grazia
    Lee, Shing Mirn
    Schwartz, Gary K.
    Carvajal, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] SBRT, Durvalumab plus -Tremelimumab in metastatic SCC: preliminary safety results of a phase I/II trial
    Levy, A.
    Bahleda, R.
    Brard, C.
    Durand-Labrunie, J.
    Hollebecque, A.
    Deutsch, E.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S57 - S58
  • [8] A phase II study of tremelimumab, durvalumab, and bevacizumab in advanced biliary tract cancers
    Coffman, Kelley Lauren
    Xie, Changqing
    Hrones, Donna M.
    Monge, B. M. Cecilia
    Kleiner, David E.
    Steinberg, Seth M.
    Redd, Bernadette
    Wood, Brad J.
    Kassin, Michael
    Levy, Elliot
    Benmebarek, Mohamed-Reda
    Greten, Tim F.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] A phase I/II trial of pemetrexed and sirolimus in advanced NSCLC
    Blumenthal, G. M.
    Ballas, M. S.
    Bernstein, W.
    Shamloo, B. K.
    Root, H.
    Helsabeck, C.
    Chun, G.
    Figg, W. D.
    Giaccone, G.
    Dennis, P. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies
    Joleen M. Hubbard
    Jun Yin
    Erin L. Schenk
    Rui Qin
    Joel M. Reid
    Carrie Strand
    Jack Fiskum
    Michael Menefee
    Grace Lin
    L. Austin Doyle
    Percy Ivy
    Charles Erlichman
    Alex Adjei
    Paul Haluska
    Brian A. Costello
    Investigational New Drugs, 2022, 40 : 115 - 123
12345